190 related articles for article (PubMed ID: 24942334)
21. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.
Kang M; Shen XJ; Kim S; Araujo-Perez F; Galanko JA; Martin CF; Sandler RS; Keku TO
Cancer Biomark; 2013; 13(5):359-66. PubMed ID: 24440976
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
[TBL] [Abstract][Full Text] [Related]
23. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
24. Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population.
Liou JM; Wu MS; Shun CT; Chiu HM; Chen MJ; Chen CC; Wang HP; Lin JT; Liang JT
Int J Colorectal Dis; 2011 Nov; 26(11):1387-95. PubMed ID: 21553007
[TBL] [Abstract][Full Text] [Related]
25. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
[TBL] [Abstract][Full Text] [Related]
26. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
[TBL] [Abstract][Full Text] [Related]
28. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
29. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
30. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
31. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
32. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Zhu K; Yan H; Wang R; Zhu H; Meng X; Xu X; Dou X; Chen D
Med Oncol; 2014 Jul; 31(7):16. PubMed ID: 24861917
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
34. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
[TBL] [Abstract][Full Text] [Related]
35. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
Popovici V; Budinska E; Bosman FT; Tejpar S; Roth AD; Delorenzi M
BMC Cancer; 2013 Sep; 13():439. PubMed ID: 24073892
[TBL] [Abstract][Full Text] [Related]
36. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
[TBL] [Abstract][Full Text] [Related]
38. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
39. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
Li HT; Lu YY; An YX; Wang X; Zhao QC
Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
[TBL] [Abstract][Full Text] [Related]
40. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
